Charles Schwab Investment Management Inc. grew its stake in shares of Insulet Co. (NASDAQ:PODD - Free Report) by 43.8% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 636,265 shares of the medical instruments supplier's stock after buying an additional 193,839 shares during the period. Charles Schwab Investment Management Inc. owned approximately 0.91% of Insulet worth $148,091,000 as of its most recent filing with the Securities and Exchange Commission.
Other institutional investors also recently modified their holdings of the company. Marshall Wace LLP bought a new position in shares of Insulet during the second quarter worth $99,978,000. Baillie Gifford & Co. increased its holdings in shares of Insulet by 30.8% in the second quarter. Baillie Gifford & Co. now owns 1,886,062 shares of the medical instruments supplier's stock worth $380,607,000 after acquiring an additional 443,783 shares in the last quarter. Mizuho Securities USA LLC lifted its holdings in shares of Insulet by 5,928.1% during the 3rd quarter. Mizuho Securities USA LLC now owns 325,821 shares of the medical instruments supplier's stock valued at $75,835,000 after purchasing an additional 320,416 shares in the last quarter. American Century Companies Inc. increased its stake in Insulet by 18.7% during the 2nd quarter. American Century Companies Inc. now owns 885,669 shares of the medical instruments supplier's stock worth $178,728,000 after purchasing an additional 139,246 shares in the last quarter. Finally, Federated Hermes Inc. raised its stake in shares of Insulet by 38.8% in the 2nd quarter. Federated Hermes Inc. now owns 369,113 shares of the medical instruments supplier's stock valued at $74,487,000 after purchasing an additional 103,266 shares during the period.
Analysts Set New Price Targets
A number of analysts have recently issued reports on PODD shares. Raymond James lifted their price objective on shares of Insulet from $213.00 to $260.00 and gave the company an "outperform" rating in a report on Monday, October 14th. Canaccord Genuity Group increased their price target on Insulet from $236.00 to $269.00 and gave the company a "buy" rating in a research report on Wednesday, September 25th. Piper Sandler boosted their price target on Insulet from $230.00 to $285.00 and gave the stock an "overweight" rating in a research report on Tuesday, September 17th. BTIG Research increased their price objective on Insulet from $260.00 to $270.00 and gave the company a "buy" rating in a report on Friday, November 8th. Finally, Citigroup increased their price objective on shares of Insulet from $250.00 to $275.00 and gave the company a "buy" rating in a research report on Tuesday, October 1st. Three research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $253.27.
Check Out Our Latest Analysis on PODD
Insulet Trading Up 1.4 %
Shares of NASDAQ:PODD traded up $3.65 during mid-day trading on Monday, reaching $266.58. 552,047 shares of the company's stock were exchanged, compared to its average volume of 773,239. The company has a debt-to-equity ratio of 1.21, a quick ratio of 2.80 and a current ratio of 3.68. Insulet Co. has a twelve month low of $160.19 and a twelve month high of $279.40. The firm has a market capitalization of $18.70 billion, a price-to-earnings ratio of 45.02, a PEG ratio of 4.02 and a beta of 1.22. The business's fifty day moving average price is $241.32 and its 200-day moving average price is $211.02.
About Insulet
(
Free Report)
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.
Featured Stories
Before you consider Insulet, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Insulet wasn't on the list.
While Insulet currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
